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ABSTRACT. Bladder cancer is the most frequent cancer of the 
urinary system. Fibroblast growth factor receptors (FGFR) belong 
to the tyrosine kinase family and have important roles in cell 
differentiation and proliferation and embryogenesis. FGFR3 is 
located on chromosome 4p16.3, and missense mutations of FGFR3 
are associated with autosomal dominant human skeletal disorders 
and have some oncogenic effects. We examined the incidence of 
FGFR3 thanatophoric dysplasia mutations located in exon 7, A248C 
and S249C, and in exon 10, G372C and T375C, and their correlation 
with clinical-pathological parameters in bladder carcinoma patients. 
Fifty-six paraffin-embedded specimens of transitional cell carcinoma 
of the urinary bladder were included in this study. Analysis of FGFR3 
thanatophoric dysplasia mutations located in exon 7, A248C and 
S249C, and in exon 10, G372C and T375C, was performed by PCR-
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restriction fragment length polymorphism (RFLP) analysis and DNA 
sequencing. FGFR3 thanatophoric dysplasia mutations located in 
exon 7, A248C and S249C, and in exon 10, G372C and T375C, were 
detected in 33 of the 56 patients (heterozygous mutant). Among the 56 
transitional cell carcinomas, missense point mutations were detected in 
seven of them at codon A248C, 28 of them at codon S249C, and three 
of them at codon T375C, similar to data from previous reports. When 
the results of the FGFR3 thanatophoric dysplasia mutations located in 
exon 7, A248C and S249C and in exon 10, G372C and T375C, were 
analyzed one by one or as a group, despite the findings of previous 
research reports, our data suggest that these mutations are detected 
homogenously regardless of the tumor classification and tumor grade.
Key words: Bladder carcinoma; Fibroblast growth factor receptor 3; 
Mutation; PCR; DNA sequencing; Transitional cell carcinoma
INTRODUCTION
Urinary bladder cancer is the fourth most common cancer type in men and the ninth 
most common cancer in women. More than 90% of bladder tumors are transitional cell carci-
nomas. Approximately 80% of transitional cell carcinomas are confined to the epithelium (pTa, 
CIS) or lamina propria (pT1) at initial diagnosis, but the remaining 20% invade the muscularis 
propria (pT2, pT3, pT4). pTa lesions (papillary tumors) are the most common form of bladder 
carcinoma (Billerey et al., 2001). The expression and mutational status of fibroblast growth 
factor receptor 3 (FGFR3) has been analyzed in a series of bladder carcinomas. Frequent ac-
tivating mutations of FGFR3 in human bladder carcinomas have been analyzed for the first 
time, and it was suggested that FGFR3 is involved in epithelial tumorigenesis (Cappellen et 
al., 1999). Mutations of FGFR3 have also been reported in more than 50% of primary blad-
der urothelial cell carcinomas, especially in low-grade and low-stage papillary tumors (Su-
gano and Kakizoe, 2006). Detection of FGFR3 mutation would be useful for low-grade and 
low-stage urothelial cell carcinomas in urine due to the higher frequency of this mutation in 
superficial bladder cancers.
The identification of mutations in FGFR3 indicates an important role in bladder car-
cinogenesis (Cappellen et al., 1999). FGFR3 belongs to the tyrosine kinase receptor family, 
which also includes FGFR1, 2 and 4 (Basilico and Moscatelli, 1992). They play important 
roles in cell proliferation and differentiation and embryonic development. These receptors 
have two or three extracellular immunoglobulin-like domains, a transmembrane domain and 
two tyrosine-kinase domains. The human FGFR3, located on chromosome 4p16.3, consists 
of 19 exons and 18 introns (Perez-Castro et al., 1997). Alternative mRNA splicing mecha-
nisms also produce different receptor isoforms, including FGFR3b and FGFR3c, which have 
different tissue expressions. FGFR3b is expressed in epithelial cells, whereas FGFR3c is the 
form found in chondrocytes. Specific point mutations in the FGFR3 gene’s different domains 
are associated with autosomal dominant human skeletal disorders such as severe achondro-
plasia with developmental delay and acanthosis nigricans (SADDAN), hypochondroplasia, 
achondroplasia, and thanatophoric dysplasia (Jaye, 1992; Johnson and Williams, 1993). 
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These mutations leading to constitutive activation of the receptor have been demonstrated 
in several reports (Partanen et al., 1993). Some mutations are involved in cell proliferation 
and differentiation by also activating the receptor tyrosine phosphorylation without a ligand. 
With this activity, an oncogenic role has been proposed for FGFR3 in multiple myeloma 
(Chesi et al., 2001). In multiple myeloma, which is a lymphoid neoplasm, a chromosomal 
translocation (t(4;14) (p16.3;q32.3)) with breakpoints on 4p16 located 50-100 kb centro-
meric to FGFR3 is present in 20-25% of tumors, and associated with overexpression of 
FGFR3. Little is known about the role of FGFR3 in epithelial carcinomas, which account 
for 90% of malignant neoplasms (Partanen et al., 1993).
Studies with low-grade papillary urothelial carcinoma showed frequent genetic al-
terations on chromosome 9, whereas chromosomal changes more specifically associated with 
aggressive bladder cancer (loss of 17p, 2q, 4p, 11p) were uncommon (Chow et al., 2000; 
Obermann et al., 2003). In a research study on patients with urothelial hyperplasia in as-
sociation with low-grade and/or high-grade urothelial carcinomas, a FGFR3 mutation was 
identified in two of the four hyperplasias accompanied by low-grade papillary urothelial 
carcinoma (Van Oers et al., 2006), providing support to the view that some lesions with 
papillary urothelial hyperplasia in patients with bladder cancer represent a neoplastic le-
sion. Furthermore, genetic alterations have frequently been observed in the normal uro-
thelium of patients with low-grade bladder cancer (Lopez-Beltran et al., 2008).
FGFR3 is expressed in normal urothelium and bladder cancer, and it is suggested 
that the mutant FGFR3 gene may have an oncogenic role in bladder cancer pathogen-
esis (Cappellen et al., 1999). In view of these findings, we investigated the incidence of 
FGFR3 TD mutations located in exon 7, A248C and S249C, and in exon 10, G372C and 
T375C, in 56 transitional cell carcinoma of the urinary bladder in Turkey. The presence 
of FGFR3 TD mutations and their correlation with clinico-pathological parameters were 
also analyzed in this study.
MATERIAL AND METHODS
Materials
Fifty-six urinary bladder transitional cell carcinoma cases from Denizli State Hospital, 
Department of Pathology archives, were included in this study. Among the 56 transitional cell 
carcinomas, 14 were classified as pTa, 23 as pT1, and 19 as pT2. In addition, 5 of them were 
graded as G1, 25 graded as G2, and 26 graded as G3. Median age at time of diagnosis was 65.5 
years (range, 28-83 years) (Table 1). All transitional cell carcinomas were staged according to 
UICC criteria and graded according to WHO criteria. Six healthy men’s genomic DNAs were 
used as the control group. This study was approved by the Pamukkale University School of 
Medicine Medical Ethics Committee.
Genomic DNA
DNA extraction from paraffin-embedded tissues was performed using the QIAamp 
DNA Mini-Kit (Qiagen, Hilden, Germany) according to the manufacturer protocol.
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DNA amplification and mutation analysis
Polymerase chain reaction (PCR) for each exon
FGFR3 TD mutations were Arg248Cys (CGC→TGC) and Ser249Cys (TCC→TGC) 
in exon 7, and Gly372Cys (GGC→TGC) and Tyr375Cys (TAT→TGT) in exon 10. Mutation 
analyses of the related exons were performed by PCR-RFLP (restriction fragment length poly-
morphism) and DNA sequencing. The primers used in this study are listed in Table 2.
Codon Exon Primer sequence PCR product (bp)
248, 249   7 F 5' CGGCAGTGGCGGTGGTGGTG 3' 120
  R 5' AGCACCGCCGTCTGGTTG 3'
372, 375 10 F 5' CAGGCCAGGCCTCAACGCCC 3' 270
  R 5' AGGCCTGGCGGGCAGGCAGC 3'
Table 2. Primers used for FGFR3 gene codon 248, 249, 372, 375 amplification.
PCR = polymerase chain reaction.
All PCR amplifications were performed in a total volume of 50 μL containing 10 μL 
extracted DNA, 20 pM of each forward and reverse primer, and 25 μL HotStarTaq Master Mix 
[containing 2.5 U HotStarTaq DNA polymerase, 1X PCR buffer with 1.5 mM MgCl2, and 200 
μM of each dNTP (Qiagen, Hilden, Germany)]. Thermal cycling conditions for PCR were as fol-
lows: initial activation of HotStarTaq DNA polymerase at 95°C for 15 min, followed by 40 cycles 
of 95°C for 1 min, 67°C for 1 min, and 72°C for 1 min, with a final extension of 72°C for 10 min 
(exon 7); initial activation of HotStarTaq DNA polymerase at 95°C for 15 min, followed by 40 
cycles of 95°C for 1 min, 72°C for 1 min, and 72°C for 1 min, with a final extension of 72°C for 
10 min (exon 10). PCR products were subjected to electrophoresis using an ethidium bromide-
stained 2% agarose gel and visualized under UV for the control of their specificity and accuracy.
Screening for Arg248Cys and Ser249Cys mutations in exon 7 using RFLP analysis
Screening for the FGFR3 Arg248Cys mutation in exon 7 was performed by digestion 
with restriction endonuclease HaeII (New England Biolab, Beverly, MA, USA). Screening for 
the FGFR3 Ser249Cys mutation in exon 7 was performed by digestion with restriction endonu-
clease TseI (New England Biolab). The PCR product, 10 µL, was digested with 1 U of each re-
striction enzyme in 20 µL for 1 h at 37°C for A248C and at 65°C for S249C. Each product was 
screened on a 3% Molecular Screening agarose gel (Roche Diagnostics GmbH, Mannheim, 
Germany), which was stained with ethidium bromide and photographed under ultraviolet light.
Screening for Gly372Cys and Tyr375Cys mutations in exon 10 using sequence analysis
FGFR3 exon 10 Gly372Cys and Tyr375Cys mutations were analyzed by direct DNA 
sequencing using the ABI PRISM 310 Genetic Analyzer at Iontek Laboratory, Istanbul, Turkey.
Statistical analysis
The relationship between the FGFR3 thanatophoric dysplasia mutations and patient 
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gender or age was evaluated using the Student t-test; cellular grades were evaluated using the 
chi-square test for independence, and the SPSS 10.0 software was used for calculations. P < 
0.05 was taken as statistically significant.
RESULTS
The incidence of FGFR3 thanatophoric dysplasia mutations located in exon 7, A248C and 
S249C, and in exon 10, G372C and T375C, was investigated in 56 transitional cell carcinomas of 
the urinary bladder. PCR-RFLP and direct DNA sequencing analysis revealed the presence of 4 
different heterozygous mutations in 38 of the 56 urinary bladder transitional cell carcinoma cases.
The FGFR3 A248C mutation in exon 7 was detected in 7 of the 56 urinary bladder tran-
sitional cell carcinoma cases (12.5%). If there were no mutations, a 120-bp PCR product was 
digested to 64- and 56-bp fragments by HaeII enzyme, naturally. When the A248C mutation in 
exon 7 was present, the 120-bp PCR product could not be digested by HaeII enzyme (Figure 1).
Figure 1. Representative photograph of the PCR products restricted with HaeII enzyme and analyzed on a 3% 
Molecular Screening agarose gel. Lanes 4, 6, 7, 8 and 9 are mutant for FGFR3 A248C. Lanes 1-3, 5, 10-13 are not 
mutant for FGFR3 A248C. M = 100-bp marker.
The FGFR3 S249C mutation in exon 7 was detected in 28 of the 56 urinary bladder tran-
sitional cell carcinoma cases (50%). When the S249C mutation was present, the PCR product 
of exon 7 was digested to 63-, 31- and 26-bp fragments by TseI enzyme. If there were no muta-
tions, the 120-bp PCR product was digested to 94- and 26-bp fragments, naturally (Figure 2).
Figure 2. Representative photograph of the PCR products restricted with TseI enzyme and analyzed on a 3% 
Molecular Screening agarose gel. Lanes 1-12 are mutant for FGFR3 S249C. Lane 13 is not mutant for FGFR3 
S249C. M = 100-bp marker.
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The FGFR3 G372C mutation in exon 10 was not detected in any of the 56 urinary 
bladder transitional cell carcinoma cases.
The FGFR3 T375C mutation in exon 10 was detected in 3 of the 56 urinary bladder 
transitional cell carcinoma cases (5.4%) by direct DNA sequencing (Figure 3).
Four of the patients had both FGFR3 A248C and S249C mutations in exon 7, 
whereas one patient had both FGFR3 S249C and T375C mutations in exon 7 and exon 10, 
respectively.
In the male control group, FGFR3 thanatophoric dysplasia mutations A248C, S249C, 
G372C, and T375C were not detected. The distribution of overall FGFR3 mutations (codons 
248, 249, 372, and 375) in relation to clinico-pathological features is shown in Table 3.
Figure 3. Representative electropherogram for FGFR3 exon 10 T375C mutation using the sequence analysis. A. 
Bladder tumor case No. 20 showing normal codon for FGFR3 T375C. B. Bladder tumor case No. 16 showing 
TAT→TGT alteration for FGFR3 exon 10 T375C mutation.
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DISCUSSION
In this study, we analyzed the incidence of FGFR3 TD mutations in 56 bladder can-
cer patients at various stages and grades. Four different FGFR3 TD mutations were selected 
(A248C, S249C, G372C, T375C), in which they were analyzed in previous studies from dif-
ferent countries, except Turkey. The S249C mutation (TCC→TGC) was the most frequently 
observed FGFR3 mutation in bladder tumors in our study (28 of 56 patients showed the S249C 
mutation, 50%). The other mutations were less frequently observed in our study: 7 of 56 pa-
tients with the A248C mutation, no patient with the G372C mutation, and 3 of 56 patients with 
the T375C mutation. Evaluation of the relationship between presence of FGFR3 TD mutations 
and patient gender/age revealed that there was no significant correlation between the occur-
rence of FGFR3 mutations and patient’s age or gender (Table 3). There was also no significant 
correlation between the presence of FGFR3 mutations and tumor grade or stage in our study.
FGFR3 mutations have been implicated in tumorigenesis for sometime (Basilico and 
Moscatelli, 1992). Somatic FGFR3 mutations identical to those found in thanatophoric dys-
plasia and SADDAN have been associated with rare cases of human multiple myeloma. Some 
of the studies have reported that low-stage and low-grade bladder tumors are associated with 
FGFR3 mutations (Cappellen et al., 1999) and alterations on chromosome 9 (Van Tilborg 
et al., 2002; Hirao et al., 2005). Billerey et al. (2001) investigated the relationship between 
FGFR3 mutations and tumor stage and found that the frequency of FGFR3 mutations was 
high in pTa tumors (74%). FGFR3 mutations were present in only 21% of pT1 and 16% of 
pT2-4 tumors. The S249C mutation (TCC→TGC) is the most frequent FGFR3 mutation in 
bladder tumors (33 of 48, 69%). Other researchers have also reported similar findings, such 
as Kimura et al. (2001) who detected TD mutations of the FGFR3 in 25 of 81 cases of transi-
tional cell carcinoma of the bladder (30.9%). This is in agreement with Wang et al. (1999)’s 
findings in which FGFR3 mutations were detected in 9 of 26 bladder carcinomas (35%). Van 
Rhijn et al. (2001) detected 34 point mutations in 72 bladder carcinomas (30 at codon 249, 1 at 
codon 248, and 2 at codon 372). In their findings, all tumors with FGFR3 mutation were pTa 
and grade 1 or 2 (Van Rhijn et al., 2001). Otto et al. (2009) found that all urothelial samples 
in their groups showed a wild-type sequence for FGFR3. They suggested for these data that 
mutations in the FGFR3 are not the earliest genetic alterations in bladder carcinogenesis, and 
they thought that these findings are associated with a hyper-proliferative phenotype in the 
Characteristic N (%) A248C S249C G372C T375C Results of thanatophoric dysplasia mutations
Gender
    Female      7 (12.5%)    1 (14.3%)      6 (85.7%) -      1 (14.3%)      6 (85.7%)
    Male    49 (87.5%)    6 (12.2%)    22 (44.9%) -    2 (4.1%)    27 (55.1%)
Tumor classification (pT)
    a 14 (25%)    2 (14.3%)      6 (42.9%) -    1 (7.1%)      8 (57.1%)
    1    23 (41.1%)  2 (8.7%)    12 (52.2%) -    1 (4.3%)    14 (60.9%)
    2    19 (33.9%)    3 (15.8%)    10 (52.6%) -    1 (5.3%)    11 (57.9%)
Cellular grade (G)
    1    5 (8.9%) 1 (20%)   1 (20%) - -   2 (40%)
    2    25 (44.6%)  3 (12%) 14 (56%) - 2 (8%) 17 (68%)
    3    26 (46.4%)     3 (11.5%) 13 (50%) -    1 (3.8%)    14 (53.8%)
Table 3. Distribution of FGFR3 mutations (codons 248, 249, 372, and 375) and their correlation with clinico-
pathological features.
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urothelium. They also suggested that chromosomal alterations such as deletions on chro-
mosome 9q could play a more important role in early urothelial alteration than mutational 
FGFR3 activation (Otto et al., 2009). Tomlinson et al. (2007) published data showing that 
FGFR3 mutations are found mostly in urothelial carcinoma patients with low-stage and low-
grade tumors. They detected a frequency of mutations in low-stage urothelial carcinoma that 
was intermediate (58%) compared to those reported in studies performed in The Netherlands 
(67%) (Tomlinson et al., 2007). Van Rhijn et al. (2002) found in one of their study that 79 
pTaG1 tumors consisted of 62 papillary urothelial neoplasms of low malignant potential and 
17 low-grade papillary urothelial carcinomas, and that according to the 2004 WHO clas-
sification system, 86% had the FGFR3 mutation. These results confirmed the association of 
mutation with low-risk urothelial carcinoma and indicated that there is a strong molecular 
relationship between urothelial papilloma and low-grade urothelial carcinoma (Van Rhijn et 
al., 2002). Miyake et al. (2007) showed FGFR3 mutations in 12 of 13 (92.3%) tumor tissues 
and 11 of 13 (84.6%) urine samples from patients with superficial bladder cancer, while no 
mutations were detected in tissues and/or urine samples from patients with muscle-invasive 
bladder cancer or chronic cystitis. Kompier et al. (2009) showed that in patients with an 
FGFR3 mutant primary tumor, mutations were detected in 81% of recurrence events. The 
19% wild-type recurrences in this group, which would escape detection by potential surveil-
lance with this assay, were 18 non-muscle-invasive G1/2 tumors, two pTaG1/2 with adjacent 
CIS, and one pT2G2 tumor.
When the results of the FGFR3 thanatophoric dysplasia mutations in exon 7, A248C 
and S249C, and in exon 10, G372C and T375C, were analyzed one by one or as a group, our 
data suggested that these mutations are detected homogenously regardless of the tumor clas-
sification and tumor grade in our study, in contrast to the findings of previous research reports. 
Further study is ongoing to elucidate the significance of FGFR3 mutations detectable in urine 
samples in the clinical management of bladder cancer patients. It would also be appropriate to 
include more early-stage and low-grade tumor samples in this research project.
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